April 27, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Jason Drory
| Re: | Alector, Inc. | |||
| Registration Statement on Form S-3 | ||||
| Filed February 28, 2023 | ||||
| File No. 333-270126 | ||||
| Acceleration Request | ||||
| Requested Date: | May 1, 2023 | |||
| Requested Time: | 4:05 p.m. Eastern Time, | |||
| or as soon thereafter as practicable | ||||
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Alector, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-270126) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation, by calling Michael Coke at (650) 565-3596.
Please direct any questions or comments regarding this acceleration request to Michael Coke.
| Sincerely, | ||
| Alector, Inc. | ||
| By: | /s/ Arnon Rosenthal | |
| Arnon Rosenthal, Ph.D. | ||
| Co-founder and Chief Executive Officer | ||
| cc: | Michael E. Coke, Wilson Sonsini Goodrich & Rosati, Professional Corporation |
| Alector 131 Oyster Point Blvd, Suite 600 |
||||
| South San Francisco, CA 94080 | alector.com |